








































Alzheimer’s disease (AD) is a progressive and 
irreversible neurodegenerative disorder [1] and the most 
common cause of dementia, affecting about 35 million 
people worldwide [2]. A three-fold increase there is 
estimated for the number of cases of AD (114 million) 
by 2050 [1]. According to statistical analyses approved 
by the World Health Organization, (WHO), AD and the 
others forms of dementia rank as the fourth cause of 
death in economically developed countries with a rate 
of 4,1% of total deaths [3,4]. The disease involves 
degeneration of certain regions of the brain, which 
results in memory loss and declining  cognitive  functions 
 
 







































and leads to a decrease in physiological functions and 
death. The neuropathological hallmarks comprise the 
production of senile plaques, the formation of 
neurofibrillary tangles, and the accumulation of 
neuronal lesions in the brain [5]. Despite that Late-
Onset AD (LOAD) has a relatively high heritability of 
around 70% [6], the sole long-established, unequivocal 
genetic risk factor has been the ε4-allele of the 
Apolipoprotein E gene (APOE) [7-10]. The precise 
mechanism by which APOE exerts this influence 
remains largely undefined, with indications including a 
key role in mediating Aβ metabolism and clearance 
[11]. Numerous candidate gene, genetic linkage, and 
association studies have been carried out over the past 
























aberrant  phosphorylation,  amyloidogenic  pathway  (APP,  BACE1),  Oxidative  Stress  (iNOS,  Aldh2)  and  inflammation
(astrogliosis, TNF‐α and IL‐6); no changes were found in non‐amyloidogenic pathway indicators such as ADAM10. 
Epigenetics  changes as higher CpG methylation and  transcriptional  changes  in DNA methyltransferases  (DNMTs)  family
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two decades to elucidate the remaining genetic risk for 
AD [12]. However, none of these candidates has proven 
to consistently influence disease risk or onset age in 
more than a handful of samples [13]. Reasons for lack 
of reproducibility may include the following: 
insufficient study power to detect variants with minor 
contributions; biologic, genetic, and allelic 
heterogeneity; difference in study design, and the 
presence of population substructure [14]. The 
occurrence of phenotypical differences in monozygotic 
twins over time is thought to arise from epigenetic 
changes induced by different environments or by 
stochastic events [15]; thus, it appears plausible that 
epigenetic changes resulting in altered gene expression 
may also be involved in the pathogenesis of LOAD. 
 
In addition to genetic factors, growing evidences 
demonstrated that the effects of environmental factors 
and epigenetic mechanisms also play an important role 
in the pathogenesis of AD [16-20]. Epigenetic 
information is principally encoded in two types of 
synergistically acting covalent modifications: DNA 
methylation and chromatin modifications; these changes 
afford the epigenetic complexity that directly affects 
regulation of the gene expression and other genomic 
functions [21].  For example, hypomethylation of the 
Amyloid Precursor Protein (APP) gene in the brain of a 
patient with AD was found [22]. Subsequently, several 
studies have linked DNA methylation changes in 
hippocampus and cortex of patients with AD, showing 
that DNA hypomethylation is associated with a huge 
number of Amyloid β (Aβ) plaques [22]. DNA 
methylation is also involved in APP processing and Aβ 
production through the regulation of Presenilin1 (PS1) 
and β-secretase (BACE) expression [23].  Monitoring 
the frontal cortex of patients with AD, indicated that 
DNA hypomethylation leads to expanded regulation of 
proinflammatory genes, Nuclear Factor-κβ (NF-κβ) and 
the encoding of cyclooxygenase-2 that catalyzes the 
production of prostaglandins and some prostanoids 
[24,25]. This assumes that abnormal DNA methylation 
may cause nerve inflammation. Hypermethylation of 
Brain Derived Neurotrophic Factor (BDNF) and cAMP 
Response Element Binding (CREB) promoters would 
harm the plasticity of the synapses [25]. Although these 
studies report AD brain global DNA methylation 
changes in opposite directions, differences are likely 
due to the fact that the authors studied different brain 
regions and employed different methylation detection 
techniques.  
 
In addition, Aβ changes in DNA methylation are 
associated with induction of several genes, causing 
apoptotic and cell loss. It remains unclear how these 
changes in DNA methylation began, but it is suggested 
that various cellular mechanisms, such as OS and Aβ-
42, are involved [26]. OS and Aβ-42 may modify DNA 
methylation, and evidences for the dynamic modulation 
of learning and memory suggest the functional 
importance of abnormal methylation of DNA in the 
cases of AD [27]. 
 
The detection and identification of mutations in APP, 
PS1 and PS2 genes associated with Familial AD (FAD) 
have allowed the generation of various transgenic 
murine models. These transgenic models have the 
potential to enable us to understand the pathogenesis of 
the disease, and to develop and evaluate new and 
effective therapeutic targets. The 5XFAD mouse was 
formally established and declared in 2006 by Oakley 
and the specific characteristic of this model being that it 
is generated to promote rapid, aggressive and complete 
development of AD pathological interactions. This 
novel model of Aβ pathology consists of two APP 
mutations (APP K67ON/ M671L (Swedish), I716V 
(Florida), and V717 (London) and two PS1 mutations 
(PS1 M146 and L286V) on B6/SJL and each transgene 
is regulated by Thy1 promoter [28,29]. 
 
The present work focuses on the study of the possible 
involvement of Aβ-42 accumulation in the production 
of OS and in subsequent modifications in the epigenetic 
machinery in the murine model of AD, 5XFAD. We 
aimed to discuss the role of global DNA methylation 
and the histone epigenetic enzymes involved in 
epigenetic modification acting in the control of gene 




5XFAD showed cognitive impairment but no 
changes in emotional parameters with age 
 
NORT analysis demonstrated significant differences 
between the 5XFAD and Wt strains at 8, but not at 2 
months of age (age, F(1,28) = 4.5631, p = 0.0416; 
genotype, F(1,28) = 4.563, p = 0.001, and interaction 
age × genotype F(1,28) = 6,211, p = 0.0189). The DI 
was significantly decreased in 5XFAD mice at 8 months 
of age compared with young 5XFAD mice and with 
age-matched Wt, indicating impairment in hippocampal 
memory processes (Fig. 1A). Although, all mouse 
groups were able to learn through trial days in the 
MWM paradigm, statistical differences were found 
comparing young 5XFAD compared with old Wt. (Fig. 
1B). On the test day, it was observed that 5XFAD mice 
aged 2 and 8 months showed impairment in spatial 
memory, with a significant decrease in time spent in the 
platform quadrant and with erratic preference for the 
platform area (age, F (1,28) = 0.8253, p = 0.3720; 
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genotype, F(1,28) = 19.67, p = 0.0001, and interaction 
age × genotype F(1,28) = 0.3977, p = 0.5334) (Figs. 1C 
and 1D).  
 
Behavioral and emotional tests showed differences in 
anxiety-like behavior, through EPM test (Figs. 2A and 
2B). Old 5XFAD mice demonstrated less anxious 
behavior, spending a longer time in open that in closed 
arms (age, F(1,32) = 0.7973, n.s.; genotype, F(1,32) = 














































F(1,32) = 5.761, p = 0.0024). Locomotor activity was 
reduced significantly in 5XFAD (age, F(1,32) = 8.123, 
p = 0.0076; genotype, F(1,32) = 0.2784, n.s., and 
interaction age × genotype F(1,32) = 6.921, p = 0.0338) 
(Fig. 2C and E) whereas vertical activity in EPM was 
significantly reduced in old 5XFAD (age, F(1,32) = 
6.167, p <0.0184; genotype, F(1,32) = 1.827, n.s., and 
interaction age × genotype F(1,28) = 6,211, p = 0.0189) 
(Fig. 2D). A summary of the parameters measured are 
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both female Wt and 5XFAD exhibited increased fear 
with age, reducing time in center zone (age, F(1,28) = 
43.25, p < 0.0001; genotype, F(1,28) = 13.57, p = 0.001, 
and interaction age × genotype F(1,28) = 2.887, n.s.) 
(Fig. 3A), increasing time in border zone (age, F(1,28) = 
34.69, p < 0.001; genotype, F(1,28) = 8.494, p = 0.0069, 
and interaction age × genotype F(1,28) = 0.9871, n.s.) 
(Fig. 3B). According to the results obtained in EPM 
paradigm, locomotor activity was reduced in 5XFAD 
aged 8 months (age, F(1,28) = 11.73, p =0.0019; geno-
type, F(1,28) = 1.021, n.s., and interaction age × geno-
type F(1,28) = 6,625, p = 0.0156)  and vertical activity or 
rears (age, F(1,28) = 23.33, p < 0.0001; genotype, F(1,28) 










































4.190, p = 0.0502) (Figs. 3C-E). A summary of results 
obtained in the OFT is depicted in Table 3. 
 
Alzheimer’s disease hallmarks and oxidative stress 
in female 5XFAD: changes with age 
 
Molecular analysis demonstrated that there a significant 
increase in BACE1 and APP gene expression (Figs. 4A 
and 4B) in 8 month-old 5XFAD compared with Wt 
(BACE1:age, F(1,8) = 0.8420, n.s.; genotype, F(1,8) = 
19.13, p = 0.0009, and interaction age × genotype F(1,8) 
= 0.0004, n.s., and APP: a ge, F(1,8) = 8.292, p = 
0.0138; genotype, F(1,8) = 3.969, n.s., and interaction 
















































BACE1 Rabbit Abcam/ab5832 1:500  
4-HNE Rabbit Abcam/ab46545 1:1000  
SOD1 Sheep Calbiochem/574597 1:1000  
sAPP beta Rabbit Covance/SIG-39138-050 1:1000  
Sinaptophysin Mouse Dako/Clone SY38 1:2000  
GAPDH Mouse Millipore/MAB374 1:2000  
NeuN Mouse Millipore/MAB377 1:1000  
GFAP Mouse Abcam/ab48050-100  1:1000 
TAU s396 Rabbit Invitrogen/44752G 1:1000  
TAU total Goat Santa cruz/sc-1995 1:1000  
Alexa Fluor 546 donkey 






Alexa Fluor 488 donkey 
















 Cell Signaling/# 7074 1:2000 
 
  
















































































































(A),Time  spent  in  center maze  (B),  Locomotor  activity  (C),  Rears/vertical  activity  (D),  Representative  track  sheets  showing
duration    dependent  changes  in  time  spent  in  and  number  of  entries  on  the  open  arm  and  closed  arm  in  EPM  (E). Data
represented as observed mean ± Standard Error of the Mean (SEM); (n = 10 for each group). *p<0.05; **p<0.01; ****p<0.0001.
  
















































































































spent  in border maze  (B),  Locomotor activity  (C) and Rears  (D). Representative  tracks  for  the OFT  (E). Data  represented as
observed mean ± Standard Error of the Mean (SEM) (n = 10 for each group). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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According to gene expression results, when protein levels 
for BACE1 were studied significant increases of BACE1 
in 5XFAD in comparison with Wt were demonstrated 
(age, F(1,8) = 0.5599, n.s.; genotype, F(1,8) = 15.05, p = 
0.0047, and interaction age × genotype F(1,8) = 11.17, p 
= 0.0102) (Fig. 4C). sAPPβ protein levels were studied as 
a indicative of APP processing and Aβ production; the 
















































old  5XFAD  compared  with  age-mated  Wt  (age,F(1,8) 
 = 1.647, n.s.; genotype, F(1,8) = 1.449, n.s., and 
interaction age × genotype F(1,8) = 18.45, p = 0.0026 
(Fig. 4D). This is in agreement with increases in 
thioflavine-S staining in 5XFAD in front over Wt, as 
described elsewhere (age, F(1,8) = 149.6, p<0.0001.; 
genotype, F(1,8) = 278.2, p<0.0001., and interaction age 




























































1,161.79 ± 89.91 1,360.81 ± 94.74 1,087.42 ± 
135.49 
764.18 ± 157.50## 
Time in zone-
Center (sec) 
34.35 ± 5.67 42.13 ± 3.45 28.93 ± 6.42 19.22 ± 4.86# 
Time in zone- 
Open Arms (sec) 
67.16 ± 7.93 59.28 ± 12.85 40.17 ± 8.96 118.25 ± 37.15$ 
Time in zone- 
Closed Arms (sec) 
198.11 ± 10.03 198.06 ± 14.87 230.15 ± 13.43 162.23 ± 35.18 
Rearings (n) 13.33 ± 1.02 17.58 ± 1.05 15.88 ± 2.15 7.57 ± 1.86####,$$ 
Defecations (n)  0.67 ± 0.27 0.83 ± 0.33 0.75 ± 0.49 0.29 ± 0.29 















2,296.28 ± 235.08 2,686.37 ± 260.57 2,083 ± 246.02 1,383.31 ± 
291.40*,##,$ 
Distance in Zone 
Center (cm) 




Distance in Zone 
Periphery  






Center (%)  16.91 ± 1.82 11.60 ± 1.63 7.00 ± 1.55** 4.81 ± 1.26***,#  
Periphery (%) 83.09 ± 0.80 88.40 ± 1.63* 93.00 ± 1.55**** 95.19 ± 1.26****,## 
Rearings (n) 25.89 ± 3.45 29.08 ± 3.20 17.29 ± 2.04 7.29 ± 2.68**,###
Defecations (n)  0.44 ± 0.19 0.33 ± 0.25 1.14 ± 0.51 0.57 ± 0.20 
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Tau hyperphosphorylation was also studied with a focus 
on pTau (Ser396), whose levels exhibited an age 
dependent increase in pTau both in Wt and in 5XFAD 
mice (age, F(1,8) = 69.06, p <0.0001; genotype, F(1,8) 
= 8.256, p = 0.0207, and interaction age × genotype 
F(1,8) = 2.108, n.s.) (Fig. 4E).  
 
OS is an earlier event in AD mouse models, including 
5XFAD.  Increased levels in SOD1 (age F(1,8) = 
17.9969, p <0.0028; genotype, F(1,8) = 6.875, p = 
0.0306, and interaction age × genotype F(1,8) = 5.446, p 
= 0.049), jointly with 4-HNE (age,  F(1,8) = 76.55, p 
<0.0001; genotype, F(1,8) = 36.13 p = 0.0003, and 
interaction age × genotype F(1,8) = 3.451, n.s.) (Figs. 
5A and 5B) were found in 5XFAD older mice and in 
reference to Wt. According to an increase in 4-HNE 






































demonstrated in older 5XFAD (age, F(1,8) = 9.098, p 
=0.0107; genotype, F(1,8) = 1.789, p = n.s., and 
interaction age × genotype F(1,8) = 16.06, p = 0.0017) 
(Fig. 5C) although not differences were found for iNOS 
gene expression among the studied groups (Fig. 5D). 
With reference to inflammation development, 
significant gene upregulation of TNF-α (age, F(1,12) = 
97.05, p <0.001; genotype, F(1,12) = 136.4, p < 0.0001, 
and interaction age × genotype F(1,12) = 135.0, p < 
0.0001) and IL-6 (age, F(1,12) = 17.74, p <0.0119; 
genotype, F(1,12) = 51.40, p < 0.04871, and interaction 
age × genotype F(1,12) = 17.74, p < 0.0012)  were 
found among animal groups. Both cytokines were 
significant higher in 8 months-old 5XFAD mice 
compared with young animals and age mated Wt 
indicating an age dependent inflammatory process 
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OS leads to gliosis and neuronal loss. In our hands 
increases in Glial Fibrillary Acidic Protein (GFAP) 
staining was found in 5XFAD animals compared with 




















































Quantification of fluorescence intensity demonstrated 
higher astrogliosis in hippocampus of 5XFAD with 
regard to Wt and significant worsening with age (See 
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cant neuronal loss measured as NeuN levels 
accompanied gliosis with strain and age (Figs. 7C and 
7D) (age, F(1,8) = 4.029, p = 0.0796; genotype, F(1,8) = 
18.53, p = 0.0026, and interaction age × genotype F(1,8) 



















































structures, measured by Synaptophysin protein levels 
was also determined in 5XFAD in reference to Wt mice 
(Figs. 7C-E) (age, F(1,8) = 6.047, n.s.; genotype, F(1,8) 
= 14.14, p = 0.0055, and interaction age × genotype 









































































































































































expression  levels  were  determined  by  real‐time  PCR.  Mean  ±  Standard  Error  of  the  Mean  (SEM)  from  five
independent experiments performed in triplicate are represented. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Epigenetic enzymes gene expression differences in 
female 5XFAD  
 
Global methylation and hydroxymethylation was 
measured by ELISA. Results demostrated a superior 
levels in DNA methylation (5-mC) in 5XFAD mice 
with respect to Wt which reached significance at the age 
of 2 (age, F(1,8) = 2.383, n.s.; genotype, F(1,8) = 29.32, 
p = 0.0006, and interaction age × genotype F(1,8) = 
2.583, n.s.)  (Fig. 8A), whereas 5-hmC presented a 
diminution trend, which was not statistically significant 
(Fig. 8B). DNMTs, HDMs and HDACs gene expression 
was determined by RT-PCR, and non-transgenic and 
5XFAD mice at ages 2 and 8 months were compared. 
The results demonstrated a significant increase in the 
levels of Dnmt1 in young transgenic mice, this rise is 
inverted at the older age being higher in Wt groups (age 
F(1,12) = 0.1417, n.s.; genotype, F(1,12) = 0.1785, n.s., 
and interaction age × genotype F(1,12) = 20.68, p = 
0.007) (Fig 8C). Dnmt3a and Dnmt3b levels increased 
in the mice at 8 months of age, being significant higher 
in 5XFAD groups (Dnmt3a: age, F(1,12) = 12.90, p 
=0.0037; genotype, F(1,12) = 63.51, p < 0.0001, and 
interaction age × genotype F(1,12) = 16.18, p = 0.0017; 
Dnmt3b: age, F(1,12) = 11.06, p =0.0060; genotype, 
F(1,12) = 20.76, p < 0.0007, and interaction age × 
genotype F(1,12) = 2.668, n.s.) (Figs. 8D-E). TET 
oxidized 5-mC and create 5-hmC, which may represent 
epigenetic markers of their own with a role for priming 
the epigenome. Tet1 was found significantly reduced in 
old 5XFAD in comparison with Wt (age, F(1,12) = 
0.4151, n.s.; genotype, F(1,12) = 0.1934, n.s. and 
interaction age × genotype F(1,12) = 25.93, p = 0.003), 
without changes in Tet2 (Fig. 8F).  
 
Another epigenetic modification is histone 
demethylation and deacetylation. Jarid1a, a specific 
H3K4 histone demethylase, increased in older 5XFAD 
(age, F(1,12) = 12.90, p =0.0037; genotype, F(1,12) = 
0.0367, n.s., and interaction age × genotype F(1,12) = 
8.272, p = 0.0139) (Fig. 9A). In addition, the results 
demonstrated significant differences in the expression 
of G9a (a specific H3K9 histone methyltranferase) 
between non-transgenic and 5XFAD mice. In Wt mice, 
there was a significant G9a increase with age, that was 
absent in 5XFAD animals (age, F(1,12) = 3.604, n.s.; 
genotype, F(1,12) = 5.779, p = 0.0333, and interaction 
age × genotype  F(1,12) = 14.61,  p = 0.0024)  (Fig. 9B).  
In terms of deacetylases, we observed a significant 
increase of Hdac2 in 2-months-old 5XFAD in terms of 
Wt, but non-significant changes in older mice (age, 
F(1,12) = 8.394, p =0.0134; genotype, F(1,12) = 2.184, 
n.s., and interaction age × genotype F(1,12) = 17.60, p = 
0.0012) (Fig. 9D). No differences in Hdac1 gene 
expression of were found in 5XFAD mice compared 
with non-transgenic mice at any age (Fig. 9C). Sirtuin 
family deacetylases as with memory were also explored. 
No significant changes were found in the gene 
expression of Sirt1 and Sirt2 (Figs. 9E-F), but an earlier 
decrease in Sirt6 expression was found in young 
transgenic mice, and in both strains in older mice (age, 
F(1,12) = 19.88, p =0.0008; genotype, F(1,12) = 2.378, 
n.s., and interaction age × genotype F(1,12) = 6.581, p = 




Epigenetic modifications such as global DNA 
methylation/hydroxymethylation, histone demethylation 
levels and histone acetylation levels play a crucial role 
in gene regulation [30]. Epigenetic changes could be the 
basis for the presentation of senescence and for 
neurodegenerative diseases, such as AD [31]. In fact, 
impaired global DNA methylation has been found in 
aged and AD brain, but in addition other changes can be 
related with AD. For example, AD brain showed hyper- 
and hypomethylated CpG islands in promoter regions 
for CREB and NF-kB genes, respectively. Moreover, 
AD brain demonstrated increased global histone H3 
acetylation and hypermethylation of the promotor 
region for the drebrin-like protein gene and many other 
epigenetic changes observed were inversely related with 
respective changes in messenger RNA and protein 
levels [25]. Because OS may be induced by Aβ, it can 
be an important contributor to DNA epigenetic 
modifications. It has been shown that ROS can 
command epigenetic modification by histone 
acetylation and deacetylation by HATs and HDACs, 
respectively, linking OS to chromatin  remodeling  [32]. 
However, the exact relationship among Aβ, ROS and 
epigenetics remains largely unknown, in terms of 
whether Aβ does, in fact, cause DNA 
methylation/demethylation or whether it is responsible 
for other epigenetic changes that exert an influence on 
the progression of AD. 
 
5XFAD mice are characterized by higher levels in 
amyloidogenic pathology [33]. These mice accumulate 
high levels of intraneuronal Aβ-42 at around 1.5 months 
of age with amyloid deposition rapidly following at 
around two months of age, first in the subiculum and 
layer 5 of the cortex and increasing rapidly with age 
[34]. Plaques spread throughout the hippocampus and 
cortex by 6 months of age. Gliosis also begins at around 
2 months of age, developing in parallel with plaque 
deposition. Synapse degeneration is also observed (at 
approximately 4 months of age) as well as neuronal loss 
and deficits in spatial learning (at approximately 4 to 5 
months of age) [35]. Tangles are not typical in this 
model but tau hyperphosphorylation has been described 
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[36,37]. We demonstrated, as expected, that in our 
hands female 5XFAD exhibited an increase in AD 
markers with age, including, an increase in APP and 
Bace1 expression, higher protein levels of BACE1 and 
sAPPβ, and higher number of amyloid plaques 
indicating the development of AD pathology as 
described elsewhere in aged 5XFAD [38]. Another 
hallmark demonstrated in these transgenic animals 
comprised the increase in oxidative environment that 
parallels with the degree of disease development [39]. 
In our hands, oxidative stress initiated with 4-HNE 
increases at 2 months of age, but a complete 
development of oxidative markers was found at older 
ages, accordingly to the higher levels of amyloid 
pathology and also of tau hyperphosphorylation. AD 
brain undergoes a general OS process, as documented 
by significant protein oxidation, lipid peroxidation, and 
DNA oxidation [40]. Interestingly, 4-HNE, a reactive 
end-product of lipid peroxidation that is found increased 
in AD brains, has been observed to bind to histone 
lysine residues. 
 
These molecular and biochemical findings are 
phenotypically demonstrated by loss in memory 
abilities and also by impairment in behavioral and 
emotional parameters in aged 5XFAD. Therefore, in our 
hands female 5XFAD initiate the AD  characteristics  as  
earlier as 2 months but the disease is completely 
developed at 8 months of age in a similar way described 


























Here we confront the implication of epigenetic changes 
with AD hallmarks in female 5XFAD (including Aβ 
deposition and OS processes), which we addressed from 
a holistic point of view, in order to demonstrate a 
possible relationship between the processes gated to 
earlier Aβ deposition that account for, in the 5XFAD 
brain, the epigenetic response, both to delay or to 
contribute the evolution of the disease. 
 
By means of this approach, we demonstrate that a 
significant increase in global DNA methylation, 
measured by 5-methylCytosine (5-mC) levels in young 
animals when Aβ initiate deposition and with 
concomitant increase of Dnmt1 and Dnmt3a. Dnmt3b is 
maintained as increased in older mice. Although no 
changes in hydroxymethylCytosine (5-hmC) levels were 
found, Tet1 but not Tet2 (which catalyze the conversion 
of 5-mC into 5-hmC) increases in 2 month-old transgenic 
mice, followed by a reduction in older animals. In 
reference to histone modification by acetylation or 
deacetylation, again we found differences in transgenic 
mice, with increases in Hdac2, Jarid1a or G9a. 
 
It was described elsewhere that DNMT3a and DNMT3b 
are essential for memory formation and that they 
participated in neuronal and synaptic plasticity changes. 
Recently, it is has been reported that DNMT3b 
moderates cognitive decline in subjects with mild 
cognitive impairment [41,42].  The  significant  changes  




































plaques SOD1 4-HNE DNMT1 HDAC2 
NORT (DI)  1.000 -0.251 0.238 -0.485*** -0.155 0.241 0.344 0.469*
EPM Time open arms   1.000 -0.208 0.480*** 0.327 0.330 -0.388 -0.392
OFT Locomotor activity    1.000 -0.424* -0.308 -0.427* 0.096 0.368
Amyloid plaques   1.000 0.721*** 0.005 0.633** -0.750***
SOD1   1.000 0.442* -0.361 -0.714***
4-HNE   1.000 0.402 -0.198
DNMT1    1.000 0.456*
HDAC2    1.000
 
The values used to calculate Partial correlation controlling for group coefficients were Amyloid pathology obtained with S‐Thioflavin 
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higher cytosine methylation, prior to the development of 
AD hallmark in this mouse, underlying the earlier 
participation for methylation processed at the onset of 
the pathology. Some authors reported that in aged mice 
there occurs a diminution in hippocampal expression of 
Dnmt3a, and that increasing this expression reverses 
memory deficits whereas knockdown in young mice 
impairs memory formation [43]. The increases in 
Dnmt3a and Dnmt3b in transgenic animals could be an 
attempt to surpass the harmful effect of the Aβ 
increment as well as the high oxidant environment that 
occurs in 5XFAD when the disease is completely 
developed, as depicted in negative correlations found 
among the results obtained in the present work (Table 4).  
 
JumonjiC (JmjC) and ARID domain, containing histone 
lysine demethylase 1a (JARID1a) increased histone 
acetylation by inhibiting histone deacetylase 1 function 
and modifying gene transcription in a demethylase-
independent manner. Jarid1a and Jarid1b catalyzed 
H3K4 demethylation contributing to the silencing of 
retinoblastoma target genes in senescent cells. 
Therefore Jarid1a and Jarid1b are tumor-suppressors 
that control cellular senescence [44]. Moreover, 
depletion of JARID1a in mammalian cells reduced per 
histone acetylation promoter, dampened gene 
expression and, for example, shortened the period of 
circadian rhythms [45]. 
 
Different histone methylations are also associated with 
behavioral disorders. G9a methylates H3K9 and this 
hypermethylation leads to the downregulation of BDNF 
[46]. It well established that BDNF plays an important 
role in neuron formation, maintenance and memory 
formation, and memory formation affects acetylation of 
H3 and H4 N-terminal tails. The lowest level of G9a 
gene expression in 5XFAD compared with non-
transgenic mice is coincident with the loss of memory 
in this AD mouse model.  
 
Finally, histone modification also plays an important 
role in epigenetic control.  Histone deacetylases have 
been implicated in memory and cognition, and 
concretely, HDAC2 plays a central role in coupling 
lysine acetylation with synaptic plasticity and its 
modulation is implicated in cognition and disease [47]. 
Sirtuins are a family of nicotinamide adenine 
dinucleotide-dependent deacetylases that are implicated 
in a number of physiological and pathological 
processes, such as control of glucose and lipid 
metabolism, cancer, genomic stability and DNA repair 
[48]. SIRT6 plays a role in synaptic function and 
neuronal maturation and may be implicated in the 
regulation of neuronal survival [49] and the 
overexpression of the SIRT6 extended life span [50]. It 
is noteworthy that, in the 5XFAD model, Hdac2 
increased significantly in 2-month old transgenic mice 
whereas diminution of Sirt6 was found. No significant 
changes were found for these and other histone 
acetylases or deactetylases tested at older age (Hdac1, 
Sirt1 and Sirt2). A very significant negative correlation 
between amyloid plaques and HDAC2 was found 
(Table 4), supporting the previously reported role of 
HDAC2 in synaptic plasticity [51] and working 
memory results obtained in 5XFAD.  
 
Our results support that the Aβ pathology that is 
characteristic for 5XFAD mouse correlates with 
behavior, OS markers and specific epigenetic enzymes 
in 5XFAD (Table 4). Depending on disease stage 
development, DNA transcription modification 
processes, such as methylation or acetylation, may form 
part of a vicious cycle involving OS because the 
increase in Aβ accumulation, and that of, in turn, Aβ 
may induce global DNA changes in methylation and 
acetylation that correlated with the progression of the 
pathology from earlier onset to final stages of the 
disease in 5XFAD, including neuronal loss, gliosis and 
the disturbances in cognition and behavior present in 




Animals. Female Wild type (Wt, n = 10) and 5XFAD 
(Tg5XFAD, n = 10) mice at both 2 and 8 months of age, 
were used. These animals had ad libitum access to a 
standard chow diet (2018 Teklad Global 18% Protein 
Rodent Diet; Harlan Teklad, Madison, WI, USA) and 
tap water and were maintained under standard 
temperature conditions (22 ± 2ºC) and 12h:12h light-
dark cycles (300 lux/0 lux). 
 
Studies were performed in accordance with the 
Institutional Guidelines for the Care and Use of 
Laboratory Animals established by the Ethical 
Committee for Animal Experimentation at the 
University of Barcelona. 
 
Behavioral and cognitive experiments 
 
Elevated Plus Maze test. This test is employed to assess 
anxiety [52]. The basic measurement is the animal's 
preference for dark, enclosed over bright, exposed 
places. The animal is placed in the center of the 
apparatus and observed for a set time.  Measurements 
include total time spent in open and closed arms (and 
central platform), as well as entries into open and closed 
arms. Each mouse was individually placed at the center 
of the maze facing one of the enclosed arms and 
allowed to explore the maze freely during a 5-min 
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observation period. Maze performance was video-
recorded for later analysis. Time spent in open arms and 
numbers of arm entries were analyzed as indices of 
emotional behavior utilizing SMART® ver. 3.0 software 
(PanLab, SLU, Spain). 
 
Open Field Test. Open Field Test (OFT) apparatus was 
constructed of white plywood (50 × 50 × 25 cm) [53]. 
Red lines were drawn on dividing the floor into 25-cm 
squares. Behavior was scored with SMART® ver. 3.0 
software, and each trial were recorded for later analysis, 
utilizing a camera fixed to the ceiling at a height of 2.1 
m situated above the apparatus. Mice were placed at the 
center, or at one of the four corners, of the Open Field 
and allowed to explore the apparatus for 5 min. After 
the 5-min test, the mice were returned to their home 
cages and the Open Field was cleaned with 70% ethyl 
alcohol and allowed to dry between tests. To assess the 
animal’s habituation process to the novelty of the arena, 
the mice were exposed to the apparatus for 5 min on 2 
consecutive days. The behaviors scored included Line 
Crossing, Center Entries, Center Stay Duration, 
Rearing, Defecation, and Urination. Each animal was 
then given a score for total locomotor activity, which 
was calculated as the sum of total distance, line crosses 
and number of rears.  
 
Novel Object Recognition Test (NORT). This test was 
conducted in a 90-degree, two-arm, 25-cm-long, 20-cm-
high maze [54]. Light intensity in the middle of the field 
was 30 lux. The objects to be discriminated were plastic 
figures (object A, 5.25-cm high, and object B, 4.75-cm 
high). First, mice were individually habituated to the 
apparatus for 10 min for 3 days. On day 4, they were 
submitted to a 10-min acquisition trial (first trial), 
during which they were placed in the maze in the 
presence of two identical novel objects (A+A or B+B) 
placed at the end of each arm. A 10-min retention trial 
(second trial) occurred 2 h later. During this second 
trial, objects A and B were placed in the maze, and the 
times that the animal took to explore the new object (tn) 
and the old object (to) were recorded. A Discrimination 
Index (DI) was defined as (tn-to)/(tn+to). In order to 
avoid object preference biases, objects A and B were 
counterbalanced so that one half of the animals in each 
experimental group were first exposed to object A and 
then to object B, whereas the other one half first saw 
object B and then object A was presented. The maze, 
the surface, and the objects were cleaned with 96º 
ethanol between the animals’ trials to eliminate 
olfactory cues. 
 
Morris Water Maze test. An open circular pool (100 cm 
in diameter, 50 cm in height) was filled halfway with 
water [55] and water temperature was maintained at 
22°C ± 1. Two principal perpendicular axes were 
defined; thus, the water surface was divided into four 
quadrants (NE, SE, SW, and NW), and five starting 
points were set (NE, E, SE, S, and SW). Four visual 
clues were placed on the walls of the tank (N, E, S, and 
W). Non-toxic white latex paint was added to make the 
water opaque, and a white escape platform was 
submerged 1 cm below the water level (approximately 
in the middle of one of the quadrants).  
 
The animal’s swimming paths were recorded by a video 
camera mounted above the center of the pool, and the 
data were analyzed with SMART® ver. 3.0 statistical 
software. The learning phase consisted of 6 days of 
trials for each mouse. The animals were submitted to 
five trials each day starting from the positions set (in 
random order) and without a resting phase between each 
trial and the subsequent one. At each trial, the mouse 
was placed gently into the water, facing the wall of the 
pool, and allowed to swim for 60 sec. If not able to 
locate the platform in this period of time, the mouse was 
guided to the platform by the investigator. Animals 
were left on the platform each time for 30 sec in order 
to allow spatial orientation. 
 
The parameters measured were latency time in finding 
the platform, time spent in each quadrant, and distance 
swum for each trial; the mean was calculated for each 
trial day. A memory test was performed at the end of 
the learning days, in which the platform was removed 
and the time spent by each mouse in each quadrant was 
measured. 
 
Brain isolation and immunoanalysis assays. Mice were 
euthanized 3 days after the last trial was conducted, and 
the brain was quickly removed from the skull. 
Hippocampus were dissected and frozen in powdered 
dry ice and maintained at −80°C for further use. Tissue 
samples were homogenized in lysis buffer containing 
phosphatase and protease inhibitors (Protease Inhibitor 
Cocktail 2, Sigma), and cytosol and nuclear fractions 
was obtained as described elsewhere. Protein 
concentration was determined by the Bradford method. 
Fifteen μg of protein was separated by Sodium Dodecyl 
Sulfate-PolyAcrylamide Gel Electrophoresis (SDS-
PAGE) (8‒15%) and transferred onto PolyVinylidene 
DiFlouride (PVDF) membranes (Millipore). The 
membranes were blocked in 5% non-fat milk in Tris-
Buffered Saline containing 0.1% Tween 20 (TBS-T) for 
1 h at room temperature, followed by overnight 
incubation at 4°C with primary antibodies diluted in 
TBS-T and 5% Bovine Serum Albumin (BSA)  (See 
details in Table 1). Membranes were then washed and 
incubated with secondary antibodies for 1 h at room 
temperature. Immunoreactive proteins were visualized 
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utilizing an Enhanced ChemiLuminescence-based 
detection kit (ECL Kit; Millipore) and digital images 
were acquired employing a ChemiDoc XRS+System 
(BioRad). Band intensities were quantified by 
densitometric analysis utilizing Image Lab software 
(BioRad) and values were normalized to GAPDH. 
 
For immunohistochemical studies, the frozen brains were 
embedded into OCT Cryostat Embedding Compound 
(Tissue-Tek, Torrance, CA, USA), cut into 20-μm-thick 
sections on a cryostat (Leyca Microsystems, Germany) at 
−20°C, and placed on slides. After 3 h of drying time at 
room temperature, the slices were fixed with acetone at 
4°C for 10 min, allowed to dry overnight, and finally 
stored at ‒20°C until their further staining. For the 
staining procedure, the brain sections were first 
rehydrated by 5-min incubation in Phosphate-Buffered 
Solution (PBS). Afterward, the blocking/permeabilization 
step was performed (20 min in PBS 1% BSA + 1% 
Triton). Following two, 5-min washings in PBS, the 
slices were incubated overnight at 4°C with the primary 
antibodies (see Table 1 for dilutions). Two further 
washings were carried out prior to incubation with the 
fluorescent secondary antibody (1 h at room temperature, 
see Table for dilutions). Finally, before mounting with 
Fluoromount-G™ (EMS, Hatfield, NJ, USA), nuclear 
staining was performed with Hoechst 2 µg/mL for 5 min 
at room temperature. Slides were allowed to dry 
overnight after mounting and image acquisition was 
performed with a fluorescence laser microscope 
(Olympus BX41; Germany). At least four images from 
four different individuals by group were analyzed with 
ImageJ/Fiji software available online from the National 
Institutes of Health, NIH). 
 
Thioflavin S staining. Slides were allowed to defreeze 
at room temperature and then were rehydrated with PBS 
solution for 5 min. Later, the brain sections were 
incubated with 0.3% thioflavin S (Sigma-Aldrich) for 
20 min at room temperature in the dark. Subsequently, 
these were submitted to washes in 3-min series, 
specifically with 80% ethanol (two washes), 90% 
ethanol (one wash), and three washes with PBS. Finally, 
the slides were mounted using Fluoromount (EMS), 
allowed to dry overnight at room temperature in the 
dark, and stored at 4ºC. Image acquisition was 
performed with an epifluorescence microscope (BX41; 
Olympus, Germany). For plaque quantification, similar 
and comparable histological areas were selected, 
focusing on adjacent positioning of the hippocampus 
and the whole cortical area. 
 
RNA extraction and gene expression determination. 
Total RNA isolation was carried out by means of Trizol 
reagent following the manufacturer’s instructions. RNA 
content in the samples was measured at 260 nm, and 
sample purity was determined by the A260/280 ratio in 
a NanoDrop™ ND-1000 (Thermo Scientific). Samples 
were also tested in an Agilent 2100B Bioanalyzer 
(Agilent Technologies) to determine the RNA integrity 
number. Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR) was performed as follows: 2 μg of 
messenger RNA (mRNA) was reverse-transcribed using 
the High Capacity (complementary DNA) cDNA 
Reverse Transcription kit (Applied Biosystems). Real-
time quantitative PCR (qPCR) was employed to 
quantify the mRNA expression of Aldehyde 
dehydrogenase 2 (Aldh2), amyloid beta  A4 Precursor 
(PreAPP), β-secretase 1 (Bace1) and Disintegrin and 
Metalloproteinase 10 (Adam10), inflammatory genes 
Interleukin 6 (IL-6) and Tumor necrosis factor alpha 
(TNF-α), inducible Nitric Oxide Synthase (iNOS), 
epigenetic enzymes genes DNA (cytosine-5-)-
methyltransferase 1 (Dnmt1), DNA (cytosine-5-)-
methyltransferase 3 alpha (Dnmt3a), DNA (cytosine-5-)-
methyltransferase 3 beta (Dnmt3b), Tet methylcytosine 
dioxygenase 1 (Tet1), Tet methylcytosine dioxygenase 
2 (Tet2), lysine (K)-specific demethylase 5A (Jarid1a), 
histone-lysine N-methyltransferase 2 (G9a), histone 
deacetylase 1 (Hdac1), histone deacetylase 2 (Hdac2), 
sirtuin 1 (Sirt1), sirtuin 2 (Sirt2), sirtuin 6 (Sirt6). 
Normalization of expression levels was performed with 
Actin for SYBER Green and TATA-binding protein 
(Tbp) for TaqMan. The primers were as follows: for 
Aldh2, forward 5'- GCAGGCGTACACAGAAGTGA-3' 
and reverse 5'-TGAGCTTCATCCCCTACCCA-3', for 
PreAPP, forward 5'- AGGACTGACCACTCGACCAG-
3' and reverse 5'- CTTCCGAGATCTCTTCCGTCT-3', 
for Bace1, forward  5'- AAGCTGCCGTCAAGTCCATC 
-3' and reverse 5'-GCGGAAGGACTGATTGGTGA-3', 
for  Adam10,  forward  5'-GGGAAGAAATGCAAGCT 
GAA-3'  and   reverse  5'-CTGTACAGCAGGGTCCTT 
GAC-3', for  IL-6,  forward  5'-ATCCAGTTGCCTTCT 
TGGGACTGA-3' and reverse 5’-TAAGCCTCCGACT 
TGTGAAGTGGT-3’, for TNF-α, forward 5'-
TCGGGGTGATCGGTCCCCAA-3' and reverse 5'-
TGGTTTGCTACGACGTGGGCT-3', for iNOS, 
forward 5'- GGCAGCCTGTGAGACCTTTG-3' and 
reverse 5'- GAAGCGTTTCGGGATCTGAA-3', for 
Dnmt1, (Mm01151063_m1),  for Dnmt3a, forward 5’- 
GGGCCACACGGCAGAG-3’           and      reverse 5’-        
CACGGTTCTCCTCCTGTTCC-3’, for  Dnmt3b, 
forward 5'-TGCCAGACCTTGGAAACCTC-3' and 
reverse 5'-GCTGGCACCCTCTTCTTCAT-3', for Tet1, 
forward 5'-CTGCCAACTACCCCAAACTCA-3' and 
reverse 5'-TCGGGGTTTTGTCTTCCGTT-3', for Tet2, 
forward 5'-CCATCATGTTGTGGGACGGA-3' and 
reverse 5'-ATTCTGAGAACAGCGACGGT-3', for 
Jarid1a, forward 5’-TCCGTGTGTCATCAGCCAAA-
3’ and reverse 5’-CAAGCCTACGCCAGAGTCAA-3’,  
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for G9a, forward 5'-TTCCTTGTCTCCCCTCCCAG-3' 
and reverse 5'-GACGGTGACAGTGACAGAGG-3', for 
Hdac1, forward 5’- TCACCGAATCCGCATGACTC-
3’ and reverse 5’-TCTGGGCGAATAGAACGCAG-3’, 
for Hdac2, forward 5’- CTATCCCGCTCTGTGCCCT-
3’ and reverse 5’- GAGGCTTCATGGGATGACCC-3’, 
for Sirt1,  forward  5’-AACACACACACAAAATCCA 
GCA-3’  and  reverse 5’-TGCAACCTGCTCCAAGGT 
AT-3’, for  Sirt2,  forward 5’-TGCAGGAGGCTCAGG 
ATTC-3’  and  reverse  5’-GTCACTCCTTCGAGGGT 
CAG-3’,  for  Sirt6,  forward 5’-GTCTCACTGTGTCC 
CTTGTCC-3’  and  reverse  5’-GCGGGTGTGATTGG 
TAGAGA-3’, for Actin,  forward 5'-CAACGAGCGGT 
TCCGAT-3' and reverse 5'-GCCACAGGTTCCATAC 
CCA-3', Tbp, (Mm00446971_m1).  
 
Real-time PCR was performed on the Step One Plus 
Detection System (Applied Biosystems) employing 
SYBR Green PCR Master Mix (Applied Biosystems). 
Each reaction mixture contained 7.5 μL of cDNA, 
whose concentration was 2 μg, 0.75 μL of each primer 
(whose concentration was 100 nM), and 7.5 μL of 
SYBR Green PCR Master Mix (2X) and for TaqMan 
gene expression assays (Applied Biosystems), each 20 
μL of TaqMan reaction, 9 μL cDNA (18ng) was mixed 
with the 1 μL 20x probe of TaqMan Gene Expression 
Assays and 10 μL of 2X TaqMan Universal PCR 
Master Mix.  
 
Data were analyzed utilizing the comparative Cycle 
threshold (Ct) method (ΔΔCt), where the actin transcript 
level was utilized to normalize differences in sample 
loading and preparation. Each sample (n=4‒5) was 
analyzed in triplicate, and the results represented the n-
fold difference of transcript levels among different 
samples. 
 
Statistical analysis. Data are expressed as the mean ± 
Standard Error of the Mean (SEM) from at least 4‒5 
samples. Data analysis was conducted using GraphPad 
Prism ver. 6 statistical software. Means were compared 
with two-way Analysis of Variance (ANOVA) and post 
hoc analysis. Comparisons between groups were 
performed by the unpaired Student t test for 
independent samples. Statistical significance was 
considered when p values were <0.05. Statistical 
outliers were performed out with the Grubs test and 
were removed from analysis. 
 
In addition, partial correlation controlling for group 
were calculated using SPSS 19.00, between the  
following variables: DI, Time in open arms, Locomotor 
activity, Amyloid plaques, SOD1, 4-HNE, DNMT1 and 
HDAC2. Partial correlation coefficients were calculated 
using the data from number of Amyloid plaques 
obtained with S-Thioflavin staining; behavioral 
parameters from NORT, EPM and OFT; protein 
expression for SOD1 and 4-HNE; and gene expression 
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